Medtronic plc

Stocks

MDT

IE00BTN1Y115

Medical Equipment, Supplies & Distribution

Market Closed - Nyse Other stock markets 16:00:02 2026-06-08 EDT			After hours 20:00:00
80.69 ^USD	-1.20%		80.98	+0.35%

06-05	Rothschild & Co Redburn Cuts Medtronic Price Target to $106 From $111, Maintains Buy Rating	MT
06-04	Medtronic Positioned for Potential Upside to Fiscal 2027 Guidance, RBC Capital Markets Says	MT

Medtronic Posts Higher 4Q Profit, Sales

Published on 06/03/2026 at 07:26 am EDT

Dow Jones

MEDTRONIC PLC

-1.20%

By Connor Hart

Medtronic said its profit and sales rose during its fiscal fourth quarter, reflecting steps the company has taken to improve business performance and drive growth.

The medical-device maker posted a profit of $1.24 billion, or 96 cents a share, for its three months ended April 24, compared with $1.06 billion, or 82 cents a share, in last year's comparable quarter.

Stripping out certain one-time items, earnings were $1.55 a share. Analysts polled by FactSet had expected adjusted earnings of $1.54 a share.

Net sales climbed 9.9% to $9.81 billion, ahead of Wall Street models for $9.62 billion. On an organic basis, sales were up 6.6%.

Cardiovascular sales jumped 14% to $3.8 billion, making it Medtronic's largest top-line contributor. Neuroscience sales rose 5% to $2.75 billion, while revenue across its medical-surgical unit climbed 8% to $2.39 billion.

"These results represent the compounding impact of deliberate choices we've made to strengthen our strategy, sharpen execution and invest in the areas that will drive our future," Chief Executive Geoff Martha said.

The company saw continued strength across some of its largest businesses, while also building momentum across emerging, high-growth opportunities, he added.

Looking ahead, Medtronic guided for adjusted earnings of $5.90 to $6 a share over the coming year, compared with analyst views for $6.05 a share. Revenue is projected to grow 6.8% to 7.3% year-over-year, on an organic basis.

Separately, Medtronic on Wednesday also raised its quarterly dividend by a penny and said it has made strategic investments into two privately held companies focused on the development of intracardiac echocardiography, or ICE, catheter technologies.

ICE catheters provide real-time, high-resolution imaging of the heart during electrophysiology procedures, according to Medtronic. The company didn't detail the investments but said they further reinforce the momentum of its cardiac ablation business.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

06-03-26 0725ET

Latest news about Medtronic plc

06-05	Rothschild & Co Redburn Cuts Medtronic Price Target to $106 From $111, Maintains Buy Rating	MT
06-04	Medtronic Positioned for Potential Upside to Fiscal 2027 Guidance, RBC Capital Markets Says	MT
06-04	Wall Street's Chip Boom Gets a Warning
06-04	CereVasc, Inc. announced that it has received $85 million in funding from Piper Sandler Merchant Banking, Johnson & Johnson Innovation - JJDC, Inc., Medtronic plc, Bain Capital Life Sciences Investors, LLC, Perceptive Advisors LLC	CI
06-04	Goldman Sachs Adjusts Price Target on Medtronic to $83 From $84, Maintains Neutral Rating	MT
06-04	UBS Adjusts Medtronic Price Target to $85 From $90, Maintains Neutral Rating	MT
06-04	Deutsche Bank Adjusts Medtronic Price Target to $78 From $100, Maintains Hold Rating	MT
06-04	CereVasc Raises $85 Million in Funding Led by Piper Sandler Merchant Banking	MT
06-04	Truist Securities Adjusts Price Target on Medtronic to $86 From $95, Maintains Hold Rating	MT
06-04	Leerink Partners Adjusts Price Target on Medtronic to $104 From $117, Maintains Outperform Rating	MT
06-04	Needham Adjusts Price Target on Medtronic to $101 From $120, Maintains Buy Rating	MT
06-04	Stifel Adjusts Price Target on Medtronic to $80 From $95, Maintains Hold Rating	MT
06-04	Jefferies Adjusts Price Target on Medtronic to $88 From $95, Maintains Hold Rating	MT
06-04	Piper Sandler Adjusts Price Target on Medtronic to $85 From $91, Maintains Neutral Rating	MT
06-04	Baird Adjusts Price Target on Medtronic to $85 From $93, Maintains Neutral Rating	MT

Chart Medtronic plc

Duration

Period

MDT: Dynamic Chart

Company Profile

Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows: - general and minimally invasive surgery (25%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.; - cardiac rhythm management (19%): implantable cardiac pacemakers, implantable defibrillators and automatic external defibrillators, cardiac ablation probes, etc.; - vascular diseases and cardiac surgery (18.1%): coronary stents, endoprostheses for aortal pathologies, distal protection systems, catheters, heart valve prostheses, auto-transfusion equipment, cardiac ablation devices, etc.; - cranial and spinal technologies (14.8%): spinal prostheses, disc prostheses, cerebral stimulation systems, bone graft technologies and mini-invasive spinal surgery, etc. The group also develops medical imagery-guided surgical navigation systems activity; - neurovascular, ear, nose and throat (ENT) and pelvic diseases (8.7%); - diabetes management (8.2%): internal and external glycemia monitoring systems and insulin pumps; - neurological disorders (5.7%): neurostimulation and pumped medication administration products, diagnostic tools, etc. ; - other (0.5%). Net sales are distributed geographically as follows: Ireland (0.3%), the United States (51.2%) and other (48.5%).

Employees

95,000

Sector

Medical Equipment, Supplies & Distribution

Calendar

06-26 - Ex-dividend date - 0.72 USD

More about the company